A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.
Nadine Arnold(University of Sheffield), Allan Lawrie(University of Sheffield)
Cited by 0
Related Papers
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
|Circulation|2016|214
MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension
|Journal of Clinical Investigation|2016|148
Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension
|Circulation|2017|144
Inhibition of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension
|The Journal of Experimental Medicine|2012|94
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome
|American Journal of Respiratory and Critical Care Medicine|2020|73